JenaValve

OverviewSuggest Edit

JenaValve Technology Inc. is engaged in design, development, manufacturing and marketing of transcatheter aortic valve replacement systems (TAVI) to treat patients with severe aortic stenosis. JenaValve is a privately-held, venture capital backed U.S. corporation with operations in Munich, Germany. The Company's TAVI products are being sold primarily in Europe. Please visit www.jenavalve.com for more information.
TypePrivate
Founded2006
HQIrvine, CA, US
Websitejenavalve.com
Employee Ratings2.5

Latest Updates

Employees (est.) (Oct 2017)60(-4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at JenaValve

Peter Wulff

Peter Wulff

CFO
Victoria E. Carr-Brendel

Victoria E. Carr-Brendel

Ph.D., Chief Executive Officer
Mark Adler

Mark Adler

Vice President of Operations
Laura Brenton

Laura Brenton

Vice President of Clinical Affairs and International Market Development
Janet Fauls

Janet Fauls

Vice President of Quality & Regulatory
Greg Mirigian

Greg Mirigian

Vice President of R&D
Show more

JenaValve Office Locations

JenaValve has offices in Irvine, München and Swillington
Irvine, CA, US (HQ)
7545 Irvine Center Dr #100
München, DE
Landsberger Str. 110
Swillington, GB
9 Astley Way
Show all (3)

JenaValve Financials and Metrics

Summary Metrics

Founding Date

2006

JenaValve total Funding

$162.5 m

JenaValve latest funding size

$50 m

Time since last funding

2 years ago

JenaValve investors

JenaValve's latest funding round in February 2020 was reported to be $50 m. In total, JenaValve has raised $162.5 m
Show all financial metrics

JenaValve Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

JenaValve Online and Social Media Presence

Embed Graph

JenaValve News and Updates

JenaValve Announces First European Commercial Implants with the Trilogy™ Heart Valve System

IRVINE, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe. The procedures, which inclu…

JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial

IRVINE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced FDA approval for the company to initiate its Investigational Device Exemption (IDE) PMA clinical trial …

JenaValve Technology Receives CE Mark for its Trilogy™ TAVI System for the Treatment of Aortic Regurgitation and Aortic Stenosis

IRVINE, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve implantation (TAVI) systems (also referred to as TAVR, or transcatheter aortic valve replacement) for the treatment of aortic valve disease, today a…

JenaValve Frequently Asked Questions

  • When was JenaValve founded?

    JenaValve was founded in 2006.

  • Who are JenaValve key executives?

    JenaValve's key executives are Peter Wulff, Victoria E. Carr-Brendel and Mark Adler.

  • How many employees does JenaValve have?

    JenaValve has 60 employees.

  • Who are JenaValve competitors?

    Competitors of JenaValve include Fluent, QuinStreet and Torchlight Technology Group.

  • Where is JenaValve headquarters?

    JenaValve headquarters is located at 7545 Irvine Center Dr #100, Irvine.

  • Where are JenaValve offices?

    JenaValve has offices in Irvine, München and Swillington.

  • How many offices does JenaValve have?

    JenaValve has 3 offices.